Arvinas entered into a license agreement with Genentech, a member of the Roche Group, for the development of new therapeutics using Arvinas’ novel PROTAC technology. Arvinas is eligible to receive development and commercialization milestone payments in excess of $300 million based on achievement of certain predetermined milestones … more

Separately, Arvinas announced the appointment of Robert Kleinfield, Ph.D., as chief development officer of the company. Dr. Kleinfield brings over 20 years of product development and project leadership experience to Arvinas, having led programs in oncology, metabolic diseases and anti-infective therapeutic areas in a variety of pharmaceutical settings … more

Arvinas has been named by FierceBiotech as one of 2015’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Arvinas is harnessing the body’s own natural quality control system to target and degrade pathogenic proteins by using bifunctional small molecules, Proteolysis-Targeting Chimeras (PROTACs) … more